ARCHITECT 7K64-35Recalls & reported problems
Abbott Ireland · ARCHITECT Total T3 Reagent Kit (500T) · Class 1
- Adverse event reports
- 4
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 4 adverse event reports that list this exact device (DI 00380740105945), received between Nov 26, 2019 and Nov 13, 2020 — classified as 4 malfunctions.
The most frequently reported specific device problem is “Low Test Results” (3 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.
Most reported problems
Device problems
- Low Test Results3
- Incorrect, Inadequate or Imprecise Result or Readings1
- Low Readings1
Patient problems
- No Known Impact Or Consequence To Patient2
- No Patient Involvement2
Recent adverse event reports
The 4 most recent of 4 reports, in the reporter's own words as published by the FDA.
MalfunctionNov 13, 2020Incorrect, Inadequate or Imprecise Result or Readings; Low Test Results; Incorrect, Inadequate or Imprecise Result or Readings; Low Test Results
THE CUSTOMER OBSERVED A DECREASE AND IMPRECISION IN ARCHITECT TOTAL T3 PATIENT VALUES WHILE PROCESSING WITH THE REAGENT LOT NUMBERS 13003UI00 AND 15506UI00. FOLLOWING PATIENT DATA WERE PROVIDED BY THE CUSTOMER. REAGENT LOTS 15506UI00 15506UI00 14378UI00: SAMPLE 1 26.09 46.5 64.46, SAMPLE 2 <25.00 35.9 55.9, SAMPLE 3 49.18 56.89, SAMPLE 4 50.49 56.79. SID 17380UI00 15506UI00 13003UI00: (B)(6) 71.07 67.54 40.81, (B)(6) 54.03 52.73 <25.00, (B)(6) 69.84 74.04 44.92, (B)(6) 62.52 75.04 53.6. NO ADVERSE IMPACT TO PATIENT MANAGEMENT WAS REPORTED.
Patient problems: No Known Impact Or Consequence To Patient
MAUDE report 10840044 ↗MalfunctionNov 12, 2020Low Test Results; Low Test Results
THE CUSTOMER REPORTED FALSELY DEPRESSED ARCHITECT TOTAL T3 (TT3) RESULTS ON THREE PATIENTS. THE RESULTS PROVIDED WERE: S1 ARCH = 351 / COBAS = 508; S2 ARCH = <25 / COBAS = 70; S3 ARCH = 33 / COBAS = 100. THERE WAS NO REPORTED IMPACT TO PATIENT MANAGEMENT.
Patient problems: No Known Impact Or Consequence To Patient
MAUDE report 10832620 ↗MalfunctionJun 17, 2020Low Test Results; Low Test Results
THE CUSTOMER REPORTED A FALSELY DECREASED ARCHITECT TOTAL T3 RESULT ON ONE PATIENT WHILE PROCESSING WITH THE REAGENT LOT 13003UI00. RESULTS PROVIDED: (B)(6) 2020 INITIAL = < 40 NG/DL, REPEAT = 60 NG/DL. NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.
Patient problems: No Patient Involvement
MAUDE report 10164860 ↗MalfunctionNov 26, 2019Low Readings; Low Readings
THE CUSTOMER REPORTED CONTROLS OUT OF RANGE LOW FOR ARCHITECT TOTAL T3 (TT3). THERE WERE NO PATIENT RESULTS PROVIDED. THERE WAS NO REPORTED IMPACT TO PATIENT MANAGEMENT.
Patient problems: No Patient Involvement
MAUDE report 9373913 ↗
Other SINGLE (SPECIFIED) ANALYTE CONTROLS (ASSAYED AND UNASSAYED) devices
- CONTOUR® NEXT 7314Ascensia Diabetes Care US Inc. · Single (Specified) Analyte Controls (Assayed And Unassayed)227 reports
- FastPack® IP SHBG FastPack® IP SHBG 30 ImmunoassayQualigen Inc. · Single (Specified) Analyte Controls (Assayed And Unassayed)2 recalls0 reports
- CONTOUR® NEXT 7377Ascensia Diabetes Care US Inc. · Single (Specified) Analyte Controls (Assayed And Unassayed)95 reports
- ARCHITECT 7K62-25Abbott Ireland · SINGLE (SPECIFIED) ANALYTE CONTROLS (ASSAYED AND UNASSAYED)94 reports
- ARCHITECT 08K2812Abbott GmbH · Single (specified) analyte controls (assayed and unassayed)1 recall12 reports
- CONTOUR® NEXT 9697Ascensia Diabetes Care US Inc. · Single (Specified) Analyte Controls (Assayed And Unassayed)56 reports
- VITROS 6192257Ortho Clinical Diagnostics · Single (specified) analyte controls (assayed and unassayed)1 recall0 reports
- McKesson 5011Mckesson Medical-Surgical Inc. · Single (Specified) Analyte Controls (Assayed And Unassayed)1 recall0 reports
Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.